Marker Therapeutics, Inc. — Director's Dealing 2015

Nov 13, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TAPIMMUNE INC (TPIV)
CIK: 0001094038
Period of Report: 2015-03-19

Reporting Person: Laskow-Pooley David (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2015-03-19	Employee Stock Option (Right to Buy)	$0.21	A	150000	Acquired	2025-03-19	Common Stock (150000)	Direct

Footnotes

F1: Represents options granted in connection with appointment as a director of the Company on March 19, 2015 under the Company's 2014 Omnibus Stock Ownership Plan. These shares shall vest monthly over a two year period. The option exercise price is the closing price on the date of the grant, March 19, 2015.